IP Library Granted Patent US 10,232,046
Granted Patent B2
US 10,232,046 · App. 15/463,698 · Granted Mar 19, 2019

Hemostatic microspheres

Inventors: Richard I. Senderoff (Edmonds, WA); Jeffrey D. Meyer (Lake Forest Park, WA); Emily N. Rollins (Seattle, WA); Steven D. Hughes (Kenmore, WA); Richard M. Garcia (Kirkland, WA); Paul D. Bishop (Fall City, WA); Gerald W. Lasser (Lynnwood, WA)
Assignee: Baxter International Inc.
A61K47/42A61K9/0024A61K9/06A61K38/4833A61K47/10A61K47/26A61K47/32A61K47/38C12Y304/21005Y10T428/2982
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,232,046
App. No.
15/463,698
Granted
Mar 19, 2019
Kind
B2
Abstract

Provided herein are hemostatic compositions. In one embodiment, the hemostatic composition includes cross-linked polymer microspheres, such as cross-linked gelatin microspheres with pores. In another embodiment, the hemostatic composition comprises an additive such as a wetting agent, a suspending agent, or both. The hemostatic compositions may also include a hemostatic agent such as thrombin, and may include a high concentration of thrombin. The hemostatic compositions may also include plasma. Also provided herein are devices for dispersing said hemostatic compositions in a diluent, and delivering said dispersed hemostatic composition. The hemostatic compositions may also fabricated with a selected geometry as administration suggests.

Claims (18)

1. A kit including a hemostatic composition comprising:

a plurality of porous cross-linked gelatin microspheres;

a wetting agent;

a suspending agent; and

thrombin

wherein the wetting agent and the suspending agent are present in a ratio of microspheres:the wetting agent and the suspending agent of 3:1 to 60:1 (w/w), wherein the wetting agent is poloxamer 188 and the suspending agent is carboxymethylcellulose, wherein the porous cross-linked gelatin microspheres have a diameter from about 50 μm to about 500 μm, inclusive, when fully hydrated, and wherein the porous cross-linked gelatin microspheres have a pore diameter from about 15 μm to about 25 μm, inclusive.

2. The kit of claim 1 , further comprising a hemostatic composition delivery device comprising at least one syringe.

3. The kit of claim 2 , wherein the syringe contains the hemostatic composition.

4. The kit of claim 1 , further comprising a diluent.

5. The kit of claim 3 , wherein the delivery device further comprises a second syringe and a diluent, wherein said diluent, optionally, contains or is plasma.

6. The kit of claim 5 , wherein the thrombin is present in the diluent.

7. The kit of claim 5 , wherein the second syringe and the syringe containing the hemostatic composition are interconnected.

8. The kit of claim 7 , wherein the syringes are interconnected by a male/female luer lock system.

9. The kit of claim 1 , wherein the hemostatic composition is a dry powder.

10. The kit of claim 1 , wherein the thrombin concentration is in a range of about 1,000 IU to about 2,000 IU per mL of rehydrated microsphere gel, inclusive.

11. The kit of claim 1 , wherein the thrombin concentration is in a range of about 1,000 IU to about 5,000 IU per mL of rehydrated microsphere gel, inclusive.

12. The kit of claim 1 , wherein the thrombin concentration is in a range of about 5,000 IU to about 50,000 IU per mL of rehydrated microsphere gel, inclusive.

13. The kit of claim 1 , wherein the hemostatic composition has been compressed into a pledget and dried.

Assignments (7)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 16, 2018
From: ZYMOGENETICS, LLC
To: THE MEDICINES COMPANY
Reel/Frame 046172/0342 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 18, 2018
From: ZYMOGENETICS, INC.
To: ZYMOGENETICS, LLC
Reel/Frame 045578/0081 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 18, 2018
From: MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
To: MALLINCKRODT PHARMA IP TRADING D.A.C.
Reel/Frame 045578/0346 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 18, 2018
From: SENDEROFF, RICHARD I.; MEYER, JEFFREY D.; ROLLINS, EMILY N.; HUGHES, STEVEN D.; GARCIA, RICHARD M.; BISHOP, PAUL D.; LASSER, GERALD W.
To: ZYMOGENETICS, INC.
Reel/Frame 045577/0932 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 18, 2018
From: THE MEDICINES COMPANY
To: MALLINCKRODT PHARMACEUTICALS IRELAND LIMITED
Reel/Frame 045578/0455 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 18, 2018
From: ZYMOGENETICS, LLC
To: THE MEDICINES COMPANY
Reel/Frame 045969/0857 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 18, 2018
From: MALLINCKRODT PHARMA IP TRADING DAC
To: BAXTER INTERNATIONAL, INC.
Reel/Frame 045578/0391 →
Continuity (4)
Division 12935114
Provisional Application 61042156 · Apr 3, 2008
Provisional Application 61150466 · Feb 6, 2009
Related Publication 20170189537A1 · Jul 6, 2017